Lantus: adverse event reports filed with FDA

39,128

reports as suspect product

0.2% of all reports · about 1,739 a year

3,718

reports, 12 months to June 2026

1,554 in the 12 months before

63.8%

marked serious by the reporter

42.7% across the class

6.4%

record death among outcomes, as reported

2,521 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Lantus reports recording the termmedian drug in insulin analog

1. Blood glucose increasedraised blood sugar reading16.2%6,355
2. Hypoglycaemialow blood sugar8.5%3,319
3. Off label useused for a purpose or in a way not on the label6.2%2,443
4. Device malfunctionthe device did not work properly5.3%2,082
5. Blood glucose decreasedlow blood sugar reading5.2%2,030
6. Hyperglycaemiahigh blood sugar4.5%1,759
7. Drug ineffectivethe medicine did not work as expected4%1,580
8. Inappropriate schedule of product administrationthe product was taken at the wrong times3.2%1,259
9. Product quality issuea problem with the product itself3.2%1,256
10. Visual impairmentreduced vision3%1,176
11. Product storage errorthe product was stored wrongly2.9%1,147
12. Malaisegeneral feeling of being unwell2.6%1,017
13. Falla fall2.6%1,013
14. Cerebrovascular accidentstroke2.5%969
15. Glycosylated haemoglobin increaseda raised HbA1c, the long-term sugar measure2.4%925
16. Weight decreasedweight loss2.2%860
17. Dizzinesslight-headedness or unsteadiness2.2%854
18. Injection site painpain where the injection was given2.1%818
19. Deaththe patient died; cause not stated by this term2%789
20. Diabetes mellitus inadequate controldiabetes not well controlled2%783
21. Headachehead pain1.9%734
22. Weight increasedweight gain1.8%714
23. Hyperhidrosisexcessive sweating1.8%703
24. Dyspnoeashortness of breath1.8%685
25. Loss of consciousnesspassing out1.7%684
26. Nauseafeeling sick1.7%681
27. Astheniaweakness or lack of energy1.7%675
28. Blood glucose abnormal1.7%670
29. Myocardial infarctionheart attack1.7%668
30. Blood glucose fluctuation1.6%621

Top 30 of 1,780 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 26 drugs in the insulin analog class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 289,293 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 69.3% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 39,128 reports.

Drugs most often listed in the same reports

Other products listed in reports where Lantus is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the insulin analog class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Lantus as a suspect or interacting product; reports listing it only as a concomitant medication (89,614) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.